AnPac Bio-Medical Science (NasdaqCM:ANPC) - Share price, News & Analysis

ANPC fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

ANPC Stock Overview

Risk Analysis

Earnings have declined by 17.3% per year over past 5 years

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($9M)

Does not have meaningful revenue (CN¥18M)

AnPac Bio-Medical Science Competitors

Acorda Therapeutics

NasdaqGS:ACOR

US$11.2m

Brickell Biotech

NasdaqCM:BBI

US$8.7m

Exicure

NasdaqCM:XCUR

US$11.0m

Aditxt

NasdaqCM:ADTX

US$9.4m

Price History & Performance

Summary of all time highs, changes and price drops for AnPac Bio-Medical Science
Historical stock prices
Current Share Price	US$0.24
52 Week High	US$4.10
52 Week Low	US$0.20
Beta	1.32
1 Month Change	-20.66%
3 Month Change	-21.99%
1 Year Change	-94.04%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-97.89%

Recent News & Updates

Aug 05

AnPac Bio appoints Yuyang Cui as co-chief executive officer

AnPac Bio-Medical (NASDAQ:ANPC) said it had appointed Yuyang Cui as co-chairman of the board and co-chief executive officer of the company. Jiawen Kang has been appointed as a member of the board of directors of the Company and a member of the Audit Committee and Nominating Committee.

Shareholder Returns

	ANPC	US Biotechs	US Market
7D	-13.5%	1.2%	1.3%
1Y	-94.0%	-23.0%	-11.7%

Return vs Industry: ANPC underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: ANPC underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is ANPC's price volatile compared to industry and market?
ANPC volatility
ANPC Average Weekly Movement	10.2%
Biotechs Industry Average Movement	12.5%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: ANPC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ANPC's weekly volatility has decreased from 16% to 10% over the past year.

About the Company

Founded	Employees	CEO	Website
2010	89	Chris Chang Yu	https://www.anpacbio.com

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People’s Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People’s Republic of China.

AnPac Bio-Medical Science Fundamentals Summary

How do AnPac Bio-Medical Science's earnings and revenue compare to its market cap?
ANPC fundamental statistics
Market Cap	CN¥62.76m
Earnings (TTM)	-CN¥104.30m
Revenue (TTM)	CN¥17.77m

3.5x

P/S Ratio

-0.6x

P/E Ratio

Is ANPC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANPC income statement (TTM)
Revenue	CN¥17.77m
Cost of Revenue	CN¥5.70m
Gross Profit	CN¥12.07m
Other Expenses	CN¥116.37m
Earnings	-CN¥104.30m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.66
Gross Margin	67.91%
Net Profit Margin	-587.01%
Debt/Equity Ratio	83.4%

How did ANPC perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is ANPC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANPC?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ANPC. This is calculated by dividing ANPC's market cap by their current preferred multiple.
What is ANPC's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	CN¥62.76m

ANPC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5x
Enterprise Value/EBITDA	-1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ANPC's PS Ratio compare to its peers?

ANPC PS Ratio vs Peers

The above table shows the PS ratio for ANPC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	14.6x
ACOR Acorda Therapeutics	0.09x	n/a	US$11.2m
BBI Brickell Biotech	18.1x	61.1%	US$8.7m
XCUR Exicure	10.1x	n/a	US$11.0m
ADTX Aditxt	29.9x	n/a	US$9.4m
ANPC AnPac Bio-Medical Science	3.5x	n/a	US$9.3m

Price-To-Sales vs Peers: ANPC is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (14.6x).

Price to Earnings Ratio vs Industry

How does ANPC's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: ANPC is good value based on its Price-To-Sales Ratio (3.5x) compared to the US Biotechs industry average (16.7x)

Price to Sales Ratio vs Fair Ratio

What is ANPC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANPC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ANPC's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ANPC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ANPC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANPC's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is AnPac Bio-Medical Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

11.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AnPac Bio-Medical Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Take a look at our analysis of ANPC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has AnPac Bio-Medical Science performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-17.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ANPC is currently unprofitable.

Growing Profit Margin: ANPC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ANPC is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.

Accelerating Growth: Unable to compare ANPC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANPC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).

Return on Equity

High ROE: ANPC has a negative Return on Equity (-769.92%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is AnPac Bio-Medical Science's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ANPC's short term assets (CN¥17.0M) do not cover its short term liabilities (CN¥43.7M).

Long Term Liabilities: ANPC's short term assets (CN¥17.0M) exceed its long term liabilities (CN¥10.5M).

Debt to Equity History and Analysis

Debt Level: ANPC's net debt to equity ratio (80%) is considered high.

Reducing Debt: Insufficient data to determine if ANPC's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANPC has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ANPC is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

Dividend

What is AnPac Bio-Medical Science current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANPC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANPC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANPC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANPC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANPC has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure

CEO

Chris Chang Yu (64 yo)

14.58yrs

Tenure

Dr. Chris Chang Yu serves as Chief Executive Officer of AnPac Bio-Medical Science Co., Ltd. from July 14, 2022 and served as Chairman of the Board from July 14, 2022 until August 02, 2022 and serves as Co-...

Leadership Team

Experienced Management: ANPC's management team is seasoned and experienced (7.3 years average tenure).

Board Members

Experienced Board: ANPC's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 178.2%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/11 00:00
End of Day Share Price	2022/08/11 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31